Nexavar (Sorafenib)

Sorafenib, the active ingredient in Nexavar, is a tyrosine kinase inhibitor presented as a 200 mg tablet for oral use. It treats advanced renal cell carcinoma, hepatocellular carcinoma, and radioiodine‑refractory differentiated thyroid carcinoma in adult patients.

GNH USA supplies Nexavar as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Sorafenib is a multi‑kinase inhibitor used in oncology for specific solid tumours.

Advanced renal cell carcinoma: prolongs progression‑free and overall survival in adult patients. Hepatocellular carcinoma: improves survival in patients with unresectable disease. Radioiodine‑refractory differentiated thyroid carcinoma: delays disease progression in adults.

Sorafenib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea: frequent loose stools. - Fatigue: persistent tiredness. - Hand‑foot skin reaction: redness, swelling or pain on palms and soles. - Hypertension: elevated blood pressure. - Nausea: feeling of sickness.

Serious or Rare Side Effects: - Cardiac ischemia or infarction: chest pain or heart attack. - Severe hepatic dysfunction: jaundice, elevated liver enzymes. - Gastrointestinal perforation: severe abdominal pain and infection.

When prescribing Sorafenib, clinicians should consider several safety precautions. - Baseline assessment: obtain liver function tests and blood pressure before starting therapy. - Cardiovascular monitoring: regularly check blood pressure and ECG for signs of ischemia. - Dermatologic evaluation: monitor for severe hand‑foot skin reaction and rash. - Drug interactions: review concomitant medications that affect CYP3A4 metabolism. - Pregnancy and lactation: avoid use in pregnant or breastfeeding women due to unknown risk. - Store at ambient temperature: keep tablets below 25 °C in the original container, protected from moisture.

Sorafenib interacts with several medicines through metabolic pathways and pharmacodynamic effects.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce sorafenib exposure. - Anticoagulants (warfarin, direct oral anticoagulants): increased bleeding risk. - QT‑prolonging agents: additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (ketoconazole, clarithromycin): may increase sorafenib levels. - St. John’s wort: potential reduction in efficacy. - Antihypertensives: may require dose adjustment due to sorafenib‑induced hypertension.